TLX591-Tx ProstACT SELECT Study Published in Cancers Journal

Data ReadoutTLX591-TxPositive

AI Analysis

Summary

Telix Pharmaceuticals announced publication of Phase 1 ProstACT SELECT study results for TLX591-Tx, a first-in-class PSMA-targeting radio-antibody-drug conjugate, in peer-reviewed journal Cancers. The study evaluated imaging concordance for patient selection using a theranostic approach.

Clinical Trial Data

Phase

Phase 1

Outcome Details

Phase 1 ProstACT SELECT study results published in Cancers journal; evaluated lesion concordance between 68Ga-PSMA-PET and SPECT imaging for patient selection

Importance:5/10

Sentiment:

0.50

TLX591-TxPSMAradio-antibody-drug conjugatetheranosticprostate cancerPhase 1publication

Related Companies

$TLX

Read the original article

Published by GlobeNewswire Clinical Studies on July 21, 2026 9:00 PM

Read Original